For a patient on apixaban (Eliquis), should I give only an apixaban dose as a bridge instead of therapeutic enoxaparin (Lovenox) before left‑heart catheterization?

No, Do Not Use Apixaban Alone as a Bridge Before Left-Heart Catheterization

For patients on apixaban (Eliquis) undergoing left-heart catheterization, simply hold the apixaban appropriately before the procedure—therapeutic enoxaparin bridging is not indicated, and continuing apixaban at its regular dose as "bridging" is not supported by guidelines.

The Evidence-Based Approach

For Diagnostic Left-Heart Catheterization (Low-to-Moderate Bleeding Risk)

The 2014 Canadian Cardiovascular Society guidelines provide clear direction for patients on direct oral anticoagulants like apixaban 1:

• Stop apixaban 1-2 days before a procedure with low bleeding risk
• Stop apixaban 2-3 days before a procedure with intermediate-to-high bleeding risk
• No bridging therapy is recommended for NOACs (including apixaban)

The FDA label for Eliquis reinforces this approach 2:

• Discontinue at least 24 hours prior to elective surgery/procedures with low bleeding risk
• Discontinue at least 48 hours prior to procedures with moderate-to-high bleeding risk
• "Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required"

Why Bridging Is Not Needed with Apixaban

The key difference between apixaban and warfarin is pharmacokinetics:

• Apixaban has a rapid offset (half-life ~12 hours), so anticoagulant effect dissipates predictably within 24-48 hours
• Warfarin requires 5 days to wear off, creating a prolonged period of subtherapeutic anticoagulation—hence the historical rationale for bridging
• The 2014 CCS guidelines explicitly state that NOACs should be restarted "nearer the latter portion" of the 24-72 hour post-procedure window because of their rapid onset 1

The Bridging Evidence (Why It Doesn't Apply Here)

The guidelines addressing bridging therapy 1, 3 specifically refer to:

• Warfarin interruption requiring LMWH/UFH bridging in high-risk patients (CHADS₂ ≥3, mechanical valves, recent stroke)
• This does NOT apply to apixaban, which doesn't create the same prolonged gap in anticoagulation

Research evidence confirms that bridging with parenteral anticoagulants during NOAC interruption offers no advantage and may increase bleeding risk 4, 5.

The Correct Periprocedural Management Algorithm

Before Left-Heart Catheterization:

1. Assess bleeding risk of the procedure:

   • Diagnostic catheterization via radial access = low bleeding risk
   • Diagnostic catheterization via femoral access = low-to-moderate bleeding risk

2. Hold apixaban appropriately:

   • 24 hours before for radial access
   • 48 hours before for femoral access or if patient has renal impairment (CrCl 30-50 mL/min)

3. Do NOT give enoxaparin or any other bridging anticoagulation

After Left-Heart Catheterization:

• Resume apixaban when hemostasis is established:

  • Typically 24 hours post-procedure for uncomplicated diagnostic catheterization 1
  • 48-72 hours if there were bleeding complications

• The 2025 ACC/AHA guidelines confirm: "Discontinue anticoagulant therapy after PCI for uncomplicated cases" 6, 7

Common Pitfalls to Avoid

1. Don't confuse apixaban management with warfarin management—the bridging literature and guidelines for warfarin do not apply to NOACs

2. Don't give "just one dose" of apixaban as bridging—this provides no benefit and may increase bleeding risk during the procedure

3. Don't use therapeutic enoxaparin bridging—this contradicts FDA labeling 2 and guideline recommendations 1

4. Don't restart apixaban too early—wait for adequate hemostasis (usually 24 hours for uncomplicated cases)

Special Consideration: If PCI Is Performed

If the diagnostic catheterization converts to PCI with stenting, the 2025 ACC/AHA guidelines are clear 6, 7:

• Continue aspirin
• Load with P2Y12 inhibitor (clopidogrel/ticagrelor)
• Discontinue anticoagulant after uncomplicated PCI
• Resume apixaban at 24 hours post-procedure when hemostasis established

The evidence shows that for patients on chronic anticoagulation undergoing PCI, uninterrupted oral anticoagulation is safer than bridging strategies 4.